SGLT-话题@MedSci

#SGLT#

125篇内容 | 2790人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1793861, encodeId=cc121e9386194, content=<a href='/topic/show?id=5a3f1621e7d' target=_blank style='color:#2F92EE;'>#SGLT#</a>, objectTitle=SGLT2抑制剂Forxiga获得欧盟和英国的批准，用于治疗慢性肾病, objectType=article, longId=215519, objectId=1da5215519ba, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1da5215519ba, replyNumber=0, likeNumber=72, createdTime=2021-10-15, rootId=0, userName=tulenzi, userId=54f9127, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1da5215519ba, moduleTitle=SGLT2抑制剂Forxiga获得欧盟和英国的批准，用于治疗慢性肾病, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1da5215519ba)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1793868, encodeId=4f561e938686e, content=<a href='/topic/show?id=5a3f1621e7d' target=_blank style='color:#2F92EE;'>#SGLT#</a>, objectTitle=Diabetes Obes Metab：肾血流动力学对SGLT-2抑制剂的反应不依赖于蛋白质摄入量, objectType=article, longId=219913, objectId=119c21991317, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=119c21991317, replyNumber=0, likeNumber=76, createdTime=2022-01-20, rootId=0, userName=tulenzi, userId=54f9127, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=119c21991317, moduleTitle=Diabetes Obes Metab：肾血流动力学对SGLT-2抑制剂的反应不依赖于蛋白质摄入量, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=119c21991317)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1793876, encodeId=90c51e93876b6, content=<a href='/topic/show?id=5a3f1621e7d' target=_blank style='color:#2F92EE;'>#SGLT#</a>, objectTitle=ACC/AHA/HFSA 2022：推荐SGLT-2抑制剂用于治疗心衰, objectType=article, longId=723398, objectId=d22be233981c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d22be233981c, replyNumber=0, likeNumber=69, createdTime=2022-11-25, rootId=0, userName=tulenzi, userId=54f9127, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d22be233981c, moduleTitle=ACC/AHA/HFSA 2022：推荐SGLT-2抑制剂用于治疗心衰, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d22be233981c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1793863, encodeId=be5b1e938638a, content=<a href='/topic/show?id=5a3f1621e7d' target=_blank style='color:#2F92EE;'>#SGLT#</a>, objectTitle=Diabetes Obes Metab：SGLT-2抑制剂对T2DM患者血清尿酸水平的影响, objectType=article, longId=218712, objectId=149f218e125c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=149f218e125c, replyNumber=0, likeNumber=69, createdTime=2022-07-06, rootId=0, userName=tulenzi, userId=54f9127, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=149f218e125c, moduleTitle=Diabetes Obes Metab：SGLT-2抑制剂对T2DM患者血清尿酸水平的影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=149f218e125c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1793867, encodeId=cd8c1e938671d, content=<a href='/topic/show?id=5a3f1621e7d' target=_blank style='color:#2F92EE;'>#SGLT#</a>, objectTitle=Drugs：SGLT-2抑制剂在治疗非糖尿病性慢性肾病中的作用, objectType=article, longId=219863, objectId=fc9021986320, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fc9021986320, replyNumber=0, likeNumber=114, createdTime=2022-07-17, rootId=0, userName=tulenzi, userId=54f9127, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fc9021986320, moduleTitle=Drugs：SGLT-2抑制剂在治疗非糖尿病性慢性肾病中的作用, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fc9021986320)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1793875, encodeId=ba8c1e9387527, content=<a href='/topic/show?id=5a3f1621e7d' target=_blank style='color:#2F92EE;'>#SGLT#</a>, objectTitle=Cardiovasc Diabetol：SGLT2抑制剂可降低糖尿病肾病患者的多种不良临床结局风险！, objectType=article, longId=301816, objectId=ce7530181602, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ce7530181602, replyNumber=0, likeNumber=84, createdTime=2022-10-01, rootId=0, userName=tulenzi, userId=54f9127, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ce7530181602, moduleTitle=Cardiovasc Diabetol：SGLT2抑制剂可降低糖尿病肾病患者的多种不良临床结局风险！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ce7530181602)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1793857, encodeId=fe241e9385718, content=<a href='/topic/show?id=5a3f1621e7d' target=_blank style='color:#2F92EE;'>#SGLT#</a>, objectTitle=Stroke：SGLT2抑制剂对糖尿病肾病患者卒中和房颤的影响, objectType=article, longId=210247, objectId=eae121024e21, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=eae121024e21, replyNumber=0, likeNumber=66, createdTime=2022-02-22, rootId=0, userName=tulenzi, userId=54f9127, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=eae121024e21, moduleTitle=Stroke：SGLT2抑制剂对糖尿病肾病患者卒中和房颤的影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=eae121024e21)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1793858, encodeId=4bdd1e93858b7, content=<a href='/topic/show?id=5a3f1621e7d' target=_blank style='color:#2F92EE;'>#SGLT#</a>, objectTitle=JAMA Intern Med：SGLT-2抑制剂 vs磺脲类药物对II型糖尿病患者死亡风险的影响, objectType=article, longId=213849, objectId=4ba12138498f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4ba12138498f, replyNumber=0, likeNumber=81, createdTime=2021-11-02, rootId=0, userName=tulenzi, userId=54f9127, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4ba12138498f, moduleTitle=JAMA Intern Med：SGLT-2抑制剂 vs磺脲类药物对II型糖尿病患者死亡风险的影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4ba12138498f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1793862, encodeId=71f21e93862bb, content=<a href='/topic/show?id=5a3f1621e7d' target=_blank style='color:#2F92EE;'>#SGLT#</a>, objectTitle=Ann Intern Med：SGLT2抑制剂 vs GLP-1 RA对有无CVD的T2D患者心血管事件风险的影响, objectType=article, longId=218049, objectId=35582180496e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=35582180496e, replyNumber=0, likeNumber=102, createdTime=2021-10-11, rootId=0, userName=tulenzi, userId=54f9127, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=35582180496e, moduleTitle=Ann Intern Med：SGLT2抑制剂 vs GLP-1 RA对有无CVD的T2D患者心血管事件风险的影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=35582180496e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1793864, encodeId=b8b81e93864fb, content=<a href='/topic/show?id=5a3f1621e7d' target=_blank style='color:#2F92EE;'>#SGLT#</a>, objectTitle=Lancet子刊：新型降糖药SGLT2抑制剂达格列净能明显保护糖尿病肾病！, objectType=article, longId=218938, objectId=389521893854, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=389521893854, replyNumber=0, likeNumber=107, createdTime=2021-10-28, rootId=0, userName=tulenzi, userId=54f9127, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=389521893854, moduleTitle=Lancet子刊：新型降糖药SGLT2抑制剂达格列净能明显保护糖尿病肾病！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=389521893854)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1793870, encodeId=edc51e93870f3, content=<a href='/topic/show?id=5a3f1621e7d' target=_blank style='color:#2F92EE;'>#SGLT#</a>, objectTitle=Diabetes：抑制SGLT2可增加空腹胰高血糖素，但不能恢复1型糖尿病患者对低血糖的逆向调节激素反应, objectType=article, longId=221699, objectId=3087221699b5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3087221699b5, replyNumber=0, likeNumber=73, createdTime=2021-12-20, rootId=0, userName=tulenzi, userId=54f9127, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3087221699b5, moduleTitle=Diabetes：抑制SGLT2可增加空腹胰高血糖素，但不能恢复1型糖尿病患者对低血糖的逆向调节激素反应, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3087221699b5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1793859, encodeId=06721e938598b, content=<a href='/topic/show?id=5a3f1621e7d' target=_blank style='color:#2F92EE;'>#SGLT#</a>, objectTitle=降糖药SGLT-2抑制剂也能治心衰？看完本文马上掌握！, objectType=article, longId=214626, objectId=4e1d214626dd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4e1d214626dd, replyNumber=0, likeNumber=86, createdTime=2022-01-14, rootId=0, userName=tulenzi, userId=54f9127, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4e1d214626dd, moduleTitle=降糖药SGLT-2抑制剂也能治心衰？看完本文马上掌握！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4e1d214626dd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1793860, encodeId=6c5a1e9386083, content=<a href='/topic/show?id=5a3f1621e7d' target=_blank style='color:#2F92EE;'>#SGLT#</a>, objectTitle=Diabetes Care：2型糖尿病患者SGLT2抑制剂与视网膜静脉阻塞风险的关系, objectType=article, longId=214922, objectId=a0cf214922cb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a0cf214922cb, replyNumber=0, likeNumber=67, createdTime=2022-01-23, rootId=0, userName=tulenzi, userId=54f9127, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a0cf214922cb, moduleTitle=Diabetes Care：2型糖尿病患者SGLT2抑制剂与视网膜静脉阻塞风险的关系, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a0cf214922cb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1793865, encodeId=fabf1e9386592, content=<a href='/topic/show?id=5a3f1621e7d' target=_blank style='color:#2F92EE;'>#SGLT#</a>, objectTitle=Nat Med：SGLT2抑制剂达格列净治疗射血分数正常心衰的效果, objectType=article, longId=219505, objectId=2f0321950544, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2f0321950544, replyNumber=0, likeNumber=57, createdTime=2022-06-29, rootId=0, userName=tulenzi, userId=54f9127, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2f0321950544, moduleTitle=Nat Med：SGLT2抑制剂达格列净治疗射血分数正常心衰的效果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2f0321950544)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1793853, encodeId=ebba1e9385399, content=<a href='/topic/show?id=5a3f1621e7d' target=_blank style='color:#2F92EE;'>#SGLT#</a>, objectTitle=Diabetes Obes Metab：SGLT2抑制剂与全因死亡率, objectType=article, longId=204445, objectId=1c7d204445bf, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1c7d204445bf, replyNumber=0, likeNumber=89, createdTime=2021-05-16, rootId=0, userName=tulenzi, userId=54f9127, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1c7d204445bf, moduleTitle=Diabetes Obes Metab：SGLT2抑制剂与全因死亡率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1c7d204445bf)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1793855, encodeId=ee671e9385570, content=<a href='/topic/show?id=5a3f1621e7d' target=_blank style='color:#2F92EE;'>#SGLT#</a>, objectTitle=BMJ：SGLT-2抑制剂或GLP-1受体激动剂治疗糖尿病的临床优势, objectType=article, longId=205766, objectId=c84a205e66fd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c84a205e66fd, replyNumber=0, likeNumber=83, createdTime=2021-11-25, rootId=0, userName=tulenzi, userId=54f9127, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c84a205e66fd, moduleTitle=BMJ：SGLT-2抑制剂或GLP-1受体激动剂治疗糖尿病的临床优势, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c84a205e66fd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1793849, encodeId=830b1e93849fe, content=<a href='/topic/show?id=5a3f1621e7d' target=_blank style='color:#2F92EE;'>#SGLT#</a>, objectTitle=BMJ：SGLT2抑制剂可降低II型糖尿病患者的心血管事件风险, objectType=article, longId=201239, objectId=bc36201239f3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bc36201239f3, replyNumber=0, likeNumber=73, createdTime=2020-11-25, rootId=0, userName=tulenzi, userId=54f9127, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bc36201239f3, moduleTitle=BMJ：SGLT2抑制剂可降低II型糖尿病患者的心血管事件风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bc36201239f3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1793848, encodeId=b0281e93848a1, content=<a href='/topic/show?id=5a3f1621e7d' target=_blank style='color:#2F92EE;'>#SGLT#</a>, objectTitle=Lancet：SGLT2抑制剂对射血分数降低的心衰患者各类预后的影响, objectType=article, longId=200115, objectId=f8af20011537, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f8af20011537, replyNumber=0, likeNumber=67, createdTime=2021-06-14, rootId=0, userName=tulenzi, userId=54f9127, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f8af20011537, moduleTitle=Lancet：SGLT2抑制剂对射血分数降低的心衰患者各类预后的影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f8af20011537)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1793854, encodeId=124a1e938547f, content=<a href='/topic/show?id=5a3f1621e7d' target=_blank style='color:#2F92EE;'>#SGLT#</a>, objectTitle=Diabetes Obes Metab：SGLT2抑制剂与DPP4抑制剂治疗患者心衰风险比较, objectType=article, longId=204761, objectId=2bc7204e618a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2bc7204e618a, replyNumber=0, likeNumber=89, createdTime=2021-04-08, rootId=0, userName=tulenzi, userId=54f9127, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2bc7204e618a, moduleTitle=Diabetes Obes Metab：SGLT2抑制剂与DPP4抑制剂治疗患者心衰风险比较, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2bc7204e618a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1793852, encodeId=7ce61e9385291, content=<a href='/topic/show?id=5a3f1621e7d' target=_blank style='color:#2F92EE;'>#SGLT#</a>, objectTitle=Circulation：SGLT2抑制剂恩格列净也具有利尿作用, objectType=article, longId=202871, objectId=fd232028e1c1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fd232028e1c1, replyNumber=0, likeNumber=77, createdTime=2020-11-05, rootId=0, userName=tulenzi, userId=54f9127, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fd232028e1c1, moduleTitle=Circulation：SGLT2抑制剂恩格列净也具有利尿作用, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fd232028e1c1)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

SGLT

2020-05-29

tulenzi (审核中...)

前往app查看评论内容

#SGLT#

SGLT2抑制剂Forxiga获得欧盟和英国的批准，用于治疗慢性肾病

2021-10-15

tulenzi (审核中...)

前往app查看评论内容

#SGLT#

Diabetes Obes Metab：肾血流动力学对SGLT-2抑制剂的反应不依赖于蛋白质摄入量

2022-01-20

tulenzi (审核中...)

前往app查看评论内容

#SGLT#

ACC/AHA/HFSA 2022：推荐SGLT-2抑制剂用于治疗心衰

2022-11-25

tulenzi (审核中...)

前往app查看评论内容

#SGLT#

Diabetes Obes Metab：SGLT-2抑制剂对T2DM患者血清尿酸水平的影响

2022-07-06

tulenzi (审核中...)

前往app查看评论内容

#SGLT#

Drugs：SGLT-2抑制剂在治疗非糖尿病性慢性肾病中的作用

2022-07-17

tulenzi (审核中...)

前往app查看评论内容

#SGLT#

Cardiovasc Diabetol：SGLT2抑制剂可降低糖尿病肾病患者的多种不良临床结局风险！

2022-10-01

tulenzi (审核中...)

前往app查看评论内容

#SGLT#

Stroke：SGLT2抑制剂对糖尿病肾病患者卒中和房颤的影响

2022-02-22

tulenzi (审核中...)

前往app查看评论内容

#SGLT#

JAMA Intern Med：SGLT-2抑制剂 vs磺脲类药物对II型糖尿病患者死亡风险的影响

2021-11-02

tulenzi (审核中...)

前往app查看评论内容

#SGLT#

Ann Intern Med：SGLT2抑制剂 vs GLP-1 RA对有无CVD的T2D患者心血管事件风险的影响

2021-10-11

tulenzi (审核中...)

前往app查看评论内容

#SGLT#

Lancet子刊：新型降糖药SGLT2抑制剂达格列净能明显保护糖尿病肾病！

2021-10-28

tulenzi (审核中...)

前往app查看评论内容

#SGLT#

Diabetes：抑制SGLT2可增加空腹胰高血糖素，但不能恢复1型糖尿病患者对低血糖的逆向调节激素反应

2021-12-20

tulenzi (审核中...)

前往app查看评论内容

#SGLT#

降糖药SGLT-2抑制剂也能治心衰？看完本文马上掌握！

2022-01-14

tulenzi (审核中...)

前往app查看评论内容

#SGLT#

Diabetes Care：2型糖尿病患者SGLT2抑制剂与视网膜静脉阻塞风险的关系

2022-01-23

tulenzi (审核中...)

前往app查看评论内容

#SGLT#

Nat Med：SGLT2抑制剂达格列净治疗射血分数正常心衰的效果

2022-06-29

tulenzi (审核中...)

前往app查看评论内容

#SGLT#

Diabetes Obes Metab：SGLT2抑制剂与全因死亡率

2021-05-16

tulenzi (审核中...)

前往app查看评论内容

#SGLT#

BMJ：SGLT-2抑制剂或GLP-1受体激动剂治疗糖尿病的临床优势

2021-11-25

tulenzi (审核中...)

前往app查看评论内容

#SGLT#

BMJ：SGLT2抑制剂可降低II型糖尿病患者的心血管事件风险

2020-11-25

tulenzi (审核中...)

前往app查看评论内容

#SGLT#

Lancet：SGLT2抑制剂对射血分数降低的心衰患者各类预后的影响

2021-06-14

tulenzi (审核中...)

前往app查看评论内容

#SGLT#

Diabetes Obes Metab：SGLT2抑制剂与DPP4抑制剂治疗患者心衰风险比较

2021-04-08

tulenzi (审核中...)

前往app查看评论内容

#SGLT#

Circulation：SGLT2抑制剂恩格列净也具有利尿作用

2020-11-05

科室
- - 订阅+
  - 更多科室
工具
服务